chronic
obstruct
pulmonari
diseas
copd
lead
caus
death
disabl
worldwid
global
burden
diseas
studi
conclud
copd
becom
third
lead
caus
death
worldwid
increas
rank
disabilityadjust
life
year
lost
acut
exacerb
copd
aecopd
associ
impair
qualiti
life
pulmonari
function
frequent
sever
aecopd
associ
especi
markedli
impair
qualiti
life
greater
longitudin
loss
pulmonari
function
copd
aecopd
character
augment
infl
ammatori
respons
macrolid
antibiot
macrocycl
lacton
provid
adequ
coverag
frequent
identifi
ed
pathogen
aecopd
gener
includ
publish
guidelin
aecopd
manag
addit
exert
broadrang
immunomodulatori
effect
vitro
vivo
well
divers
action
suppress
microbi
virul
factor
macrolid
antibiot
use
success
treat
number
chronic
infl
ammatori
lung
disord
includ
diffus
panbronchiol
asthma
noncyst
fi
brosi
associ
bronchiectasi
cystic
fi
brosi
data
copd
patient
limit
contradictori
major
hint
potenti
clinic
biolog
effect
addit
prospect
control
data
requir
defi
ne
potenti
treatment
effect
natur
effect
role
bronchiectasi
baselin
colon
cormorbid
chronic
obstruct
pulmonari
diseas
copd
affect
million
peopl
unit
state
fourth
lead
caus
death
account
death
worldwid
copd
sixth
lead
caus
death
petti
ward
et
al
halbert
et
al
wouter
condit
top
caus
death
increas
preval
mortal
pauwel
et
al
mannino
et
al
petti
stoller
global
burden
diseas
studi
undertaken
world
bank
world
health
organ
conclud
copd
becom
third
lead
caus
death
worldwid
rank
rel
number
disabilityadjust
lifeyear
lost
increas
gulsvik
current
oxygen
therapi
hypoxem
patient
cigarettesmok
cessat
intervent
known
alter
natur
histori
copd
although
exact
defi
nition
acut
exacerb
copd
aecopd
remain
controversi
pauwel
et
al
gener
accept
defi
nition
sustain
worsen
patient
condit
stabl
state
beyond
normal
daytoday
variat
acut
onset
necessit
chang
regular
medic
patient
underli
copd
rodriguesroisin
acut
exacerb
copd
aecopd
account
million
offi
ce
visit
year
us
niederman
et
al
sethi
gonzal
et
al
account
total
cost
copd
us
europ
ward
et
al
mcguir
et
al
strassel
et
al
andersson
et
al
miravitl
et
al
acut
exacerb
copd
result
sixth
highest
use
hospit
bed
daysyr
us
million
sixth
highest
number
day
lost
work
million
druss
et
al
aecopd
major
sourc
healthcar
expenditur
cost
particularli
evid
aecopd
requir
hospit
miravitl
et
al
oostenbrink
ruttenvan
molken
neg
implic
aecopd
highlight
numer
investig
review
eighteen
studi
confi
rmed
aecopd
worsen
healthrel
qualiti
life
hrql
schmier
et
al
twoyear
longitudin
studi
note
frequent
exacerb
deleteri
effect
health
statu
patient
moder
diseas
forc
expiratori
volum
one
second
fev
predict
greatest
improv
hrql
occur
fi
rst
four
week
singl
episod
although
continu
improv
occur
week
convers
recurr
aecopd
markedli
attenu
improv
spencer
et
al
aecopd
also
result
measur
albeit
modest
acut
effect
pulmonari
function
seemung
et
al
modest
improv
pulmonari
function
particularli
lung
volum
report
fi
rst
sever
week
therapi
initi
parker
et
al
stevenson
et
al
repeat
aecopd
associ
loss
pulmonari
function
decrement
fev
rang
mlyr
patient
frequent
episod
donaldson
et
al
kanner
et
al
thu
aecopd
associ
signifi
cant
healthcar
expenditur
deterior
hrql
may
sustain
appreci
deterior
pulmonari
function
accordingli
prevent
aecopd
reduc
sever
favor
clinic
physiolog
econom
effect
copd
patient
past
sever
year
numer
studi
confi
rmed
import
role
infl
ammat
airway
lung
parenchyma
copd
hill
et
al
sethi
aaron
et
al
gompertz
et
al
wedzicha
pietila
thoma
white
et
al
mani
advoc
central
pathogen
role
infl
ammatori
respons
hogg
et
al
shapiro
ingenito
trave
donnelli
wouter
infl
ammatori
respons
contribut
increas
oxid
stress
note
aecopd
tsoumakid
et
al
neutrophil
eosinophil
infl
ammat
describ
multitud
infl
ammatori
mediat
implic
includ
leukotrien
ltb
tumor
necrosi
granulocytemacrophag
coloni
stimul
factor
gmcsf
regul
upon
activ
normal
cell
expressedsecret
rant
hill
et
al
sethi
gompertz
et
al
roland
et
al
white
et
al
one
group
follow
patient
copd
emphysemat
phenotyp
year
develop
aecopd
associ
expector
sputum
adequ
analysi
fujimoto
et
al
aecopd
total
sputum
cell
lymphocyt
neutrophil
eosinophil
neutrophil
elastas
eosinophil
cation
protein
ecp
rant
increas
compar
stabl
state
prospect
studi
use
bronchoscop
techniqu
confi
rmed
increas
express
rant
surfac
epithelium
subepitheli
lymphomononuclear
cell
increas
number
neutrophil
well
increas
aecopd
zhu
et
al
qiu
et
al
drost
et
al
collect
data
confi
rm
local
infl
ammatori
process
increas
oxid
stress
statu
exacerb
novel
pathway
promulg
infl
ammatori
respons
recent
defi
ned
ito
et
al
copd
progress
lung
infi
ltrate
activ
macrophag
rutger
et
al
amin
et
al
caramori
adcock
lymphocyt
saetta
et
al
oshaughnessi
et
al
hogg
et
al
macrophag
lymphocyt
increas
airway
alveoli
copd
di
stefano
et
al
shapiro
ingenito
preval
two
cell
type
rather
neutrophil
previous
suspect
correl
sever
airfl
ow
obstruct
di
stefano
et
al
oshaughnessi
et
al
kemeni
et
al
hill
et
al
turato
et
al
hogg
et
al
emphysema
finkelstein
et
al
russel
thorley
et
al
macrophag
key
cell
innat
immun
system
secret
cytokin
chemokin
stimul
pathogenassoci
molecular
pattern
pamp
mani
lung
lymphocyt
type
cytokineproduc
cell
saetta
et
al
saetta
et
al
saetta
et
al
majo
et
al
grumelli
et
al
cell
predomin
evid
studi
use
chronic
bronchiti
entri
criteria
saetta
et
al
less
evid
studi
design
select
chronic
bronchiti
hogg
et
al
role
macrolid
therapi
chronic
obstruct
pulmonari
diseas
although
macrophag
cell
could
synergist
contribut
progress
lung
destruct
copd
sever
way
barn
et
al
exact
mechan
remain
unproven
system
natur
copd
aecopd
recent
document
agusti
plasma
fi
brinogen
creactiv
protein
concentr
increas
aecopd
dev
et
al
wedzicha
roland
et
al
hurst
et
al
variou
infecti
noninfecti
stimuli
stimul
infl
ammatori
respons
associ
aecopd
environment
pollut
includ
particul
matter
nonparticul
gase
provok
infl
ammatori
respons
invitro
invivo
devalia
et
al
ohtoshi
et
al
rudel
et
al
epidemiolog
studi
suggest
increas
respiratori
symptom
mortal
time
increas
air
pollut
sunyer
et
al
garciaaymerich
et
al
sunyer
et
al
despit
data
larg
proport
aecopd
felt
refl
ect
infect
whether
bacteri
viral
sethi
viral
infect
well
recogn
caus
aecopd
wilkinson
et
al
johnston
frequent
report
agent
includ
rhinoviru
coronaviru
infl
uenza
parainfl
uenza
adenoviru
respiratori
syncyti
viru
rsv
human
metapneumoviru
stott
et
al
gump
et
al
seemung
et
al
greenberg
rhode
et
al
tan
et
al
pletz
et
al
wedzicha
hamelin
et
al
atyp
infecti
agent
includ
chalmydia
pneumonia
mycoplasma
pneumonia
legionella
speci
report
caus
aecopd
although
major
data
involv
c
pneumonia
beati
et
al
blasi
et
al
mogulkoc
et
al
karnak
et
al
lieberman
et
al
seemung
et
al
etiolog
role
bacteria
individu
aecopd
episod
subject
much
controversi
hirschmann
murphi
et
al
recent
comprehens
review
highlight
evolut
concept
sethi
murphi
sethi
sputum
cultur
classic
methodolog
approach
identifi
potenti
pathogen
bacteria
aecopd
frequent
isol
organ
nontyp
haemophilu
infl
uenza
moraxella
catarrhali
streptococcu
pneumonia
less
frequent
identifi
ed
organ
includ
haemophilu
parainfl
uenza
staphylococcu
aureu
pseudomona
aeruginosa
gramneg
rod
pseudomona
spp
enter
gramneg
rod
identifi
ed
sputum
patient
greater
airfl
ow
obstruct
eller
et
al
miravitl
et
al
prior
use
antimicrobi
agent
monso
et
al
bronchoscop
studi
use
bronchoalveolar
lavag
protect
specimen
brush
confi
rmed
potenti
pathogen
bacteria
identifi
ed
mani
copd
patient
baselin
aecopd
fagon
et
al
monso
et
al
pela
et
al
soler
et
al
analysi
pool
data
six
publish
studi
confi
rmed
high
frequenc
colon
stabl
copd
patient
contrast
healthi
subject
clear
shift
higher
potenti
pathogen
organ
load
note
aecopd
rosel
et
al
importantli
sever
group
demonstr
bacteri
colon
defi
ned
sputum
cultur
associ
greater
sputum
system
infl
ammatori
respons
frequent
clinic
aecopd
episod
greater
symptom
wors
health
statu
soler
et
al
bresser
et
al
hill
et
al
patel
et
al
novel
methodolog
approach
provid
even
compel
data
implic
bacteri
pathogen
aecopd
longitudin
use
sputum
cultur
molecular
type
bacteri
pathogen
isol
sputum
demonstr
acquisit
bacteri
strain
patient
previous
infect
associ
greater
twofold
increas
risk
exacerb
although
identifi
cation
new
strain
nontyp
h
infl
uenza
associ
symptomat
exacerb
major
patient
collabor
work
highlight
inher
differ
new
h
infl
uenza
strain
associ
symptomat
exacerb
lead
greater
neutrophil
recruit
adher
epitheli
cell
greater
releas
epitheli
cell
cultur
compar
associ
clinic
respons
chin
et
al
similar
approach
confi
rmed
increas
risk
aecopd
catarrhali
murphi
et
al
immun
respons
one
microbi
pathogen
util
recent
defi
ne
role
bacteria
individu
aecopd
episod
methodolog
approach
wide
report
h
infl
uenza
catarrhali
musher
et
al
yi
et
al
bakri
et
al
sethi
murphi
et
al
examin
interact
bacteri
viral
infect
one
studi
exacerb
associ
evid
acut
viral
infect
wherea
associ
develop
new
serum
igg
homolog
h
infl
uenza
isol
evid
viral
infect
identifi
ed
exacerb
data
show
viral
bacteri
infect
coexist
symptomat
aecopd
although
anteced
viral
infect
requir
h
infl
uenzaeassoci
exacerb
given
compel
data
bacteri
infect
like
etiolog
approxim
aecopd
surpris
antimicrobi
therapi
intens
studi
diseas
numer
placebocontrol
trial
antibiot
aecopd
publish
systemat
review
suggest
modest
treatment
effect
favor
antimicrobi
therapi
bach
et
al
mccrori
et
al
saint
et
al
saint
colleagu
examin
nine
placebo
control
trial
conclud
small
statist
signifi
cant
improv
antibiot
therapi
especi
signifi
cant
patient
low
baselin
fl
ow
rate
american
colleg
chest
physician
american
colleg
physician
american
societi
intern
medicin
systemat
analyz
random
placebocontrol
studi
antibiot
treatment
also
conclud
antibiot
benefi
cial
bach
et
al
mccrori
et
al
snow
et
al
addit
studi
publish
sinc
systemat
review
publish
allegra
colleagu
note
overal
clinic
respons
rate
improv
amoxicillinclavulan
versu
placebo
multicent
trial
welldefi
ned
aecopd
respons
clearli
vari
sever
baselin
airfl
ow
obstruct
greatest
differ
placebo
antimicrobi
agent
note
patient
lowest
fev
nouria
colleagu
demonstr
dramat
improv
ofl
oxacin
therapi
compar
placebo
group
patient
sever
copd
admit
respiratori
failur
base
data
recent
intern
guidelin
incorpor
recommend
aecopd
patient
like
bacteri
infect
like
benefi
antimicrobi
agent
blasi
et
al
patient
least
two
cardin
symptom
aecopd
increas
dyspnea
increas
sputum
product
andor
chang
sputum
color
experi
benefi
antibiot
therapi
anthonisen
et
al
exacerb
associ
sputum
purul
may
also
like
benefi
antibiot
treatment
stockley
et
al
wilson
increas
sputum
purul
clearli
associ
bacteri
growth
sputum
sampl
allegra
et
al
blasi
et
al
measur
serum
procalcitonin
level
recent
suggest
defi
ne
aecopd
patient
higher
likelihood
bacteri
infect
reichenberg
et
al
christcrain
et
al
henc
avail
data
suggest
antimicrobi
therapi
provid
benefi
care
select
patient
sever
diseas
sever
exacerb
numer
control
trial
compar
newer
agent
establish
one
studi
gener
design
noninferior
trial
registr
purpos
therefor
provid
limit
compar
inform
regard
clinic
respons
variou
antimicrobi
class
miravitl
torr
sethi
wilson
surprisingli
clinic
respons
trial
gener
similar
among
differ
antimicrobi
class
howev
recent
trial
use
novel
experiment
design
suggest
interest
differ
differ
antimicrobi
class
exampl
defi
ning
bacteri
erad
sputum
cultur
white
colleagu
note
patient
persist
bacteria
ten
day
cours
antimicrobi
therapi
exhibit
elev
sputum
infl
ammatori
marker
addit
investig
suggest
rapid
resolut
symptom
may
seen
quinolon
contrast
compar
agent
martinez
et
al
data
suggest
erad
bacteri
pathogen
may
associ
import
clinic
outcom
provoc
data
revolv
around
find
agent
may
lengthen
diseasefre
interv
dfi
ie
time
exacerb
anzueto
et
al
saint
et
al
chodosh
wilson
antimicrobi
therapi
complet
erad
bacteria
associ
reduc
infl
ammat
white
et
al
agent
result
greater
symptomat
resolut
better
longterm
clinic
outcom
anzueto
et
al
chodosh
wilson
base
consider
aecopd
clinic
trial
increasingli
incorpor
assess
differ
antibiot
affect
dfi
martinez
et
al
earli
studi
demonstr
equival
antibiot
shortterm
clinic
respons
although
posthoc
analysi
suggest
failur
clear
organ
sputum
posttherapi
associ
shorter
dfi
chodosh
et
al
wilson
colleagu
note
fewer
recurr
aecopd
gemifl
oxacin
compar
clarithromycin
p
mosaic
studi
investig
contrast
moxifloxacin
variou
compar
cefuroxim
clarithromycin
amoxicillin
although
antibiot
result
equival
shortterm
clinic
role
macrolid
therapi
chronic
obstruct
pulmonari
diseas
respons
moxifloxacintr
patient
requir
fewer
addit
antibiot
experienc
longer
dfi
contrast
lode
colleagu
demonstr
differ
levofl
oxacin
clarithromycin
respect
dfi
although
patient
popul
bit
less
ill
thu
effect
antibiot
class
dfi
remain
crucial
endpoint
futur
studi
aecopd
gener
macrolid
provid
adequ
coverag
frequent
identifi
ed
pathogen
aecopd
martinez
although
differ
among
compound
h
infl
uenza
activ
evid
exampl
azithromycin
appear
improv
bacteriolog
clinic
activ
rel
clarithromycin
martinez
et
al
role
macrolid
aecopd
therapi
remain
controversi
although
gener
includ
publish
guidelin
balter
et
al
martinez
woodhead
et
al
blasi
et
al
guidelin
usual
advoc
stratifi
cation
patient
likelihood
clinic
failur
macrolid
therapi
suggest
patient
milder
underli
diseas
low
likelihood
infect
organ
cover
standard
antibiot
regimen
eg
p
aeruginosa
drugresist
bacteria
host
factor
predict
treatment
failur
macrolid
macrocycl
lacton
consist
greater
ring
larg
class
compound
compris
natur
substanc
isol
fungi
organ
well
synthet
molecul
similar
structur
jain
danzig
commonli
clinic
use
agent
semisynthet
ring
antibiot
relat
erythromycin
figur
includ
erythromycin
roxithromycin
clarithromycin
typic
member
class
azithromycin
prototyp
compound
labro
macrolid
antibiot
bind
ribosom
prokaryot
eukaryot
inhibit
transpeptid
transloc
nascent
peptid
macrolid
good
bioavail
oral
rout
superb
tissu
penetr
favor
sideeffect
profi
le
prolong
tissu
persist
reason
broad
effi
caci
gramposit
gramneg
mycobacteri
chlamydi
mycoplasm
legionella
speci
macrolid
well
establish
therapi
respiratori
infect
macrolid
exert
broadrang
immunomodulatori
effect
mammalian
cell
vitro
vivo
comprehens
review
other
briefl
summar
tabl
among
mani
activ
macrolid
shown
exert
effect
wide
rang
cell
includ
nasal
bronchial
epitheli
cell
alveolar
macrophag
monocyt
eosinophil
neutrophil
lymphocyt
effect
signal
pathway
includ
desaki
et
al
kikuchi
et
al
evid
figur
macrolid
exert
host
effect
collect
limit
tissu
damag
neutrophil
addit
effect
chemoattract
includ
inhibit
oxid
burst
impair
ing
degranul
increas
rate
neutrophil
apoptosi
also
evid
macrolid
decreas
mucu
viscos
tamaoki
et
al
suppress
angiogenesi
yasunami
hayashi
importantli
immunomodulatori
effect
evid
concentr
attain
clini
calli
lowdos
administr
seen
use
macrolid
immuno
modulatori
effect
share
agent
although
case
effect
vari
among
individu
compound
exampl
roxithromycin
appear
exhibit
consist
effect
vitro
vivo
agen
et
al
scaglion
rossoni
similarli
clarithromycin
azithromycin
induc
apoptosi
peripher
blood
lymphocyt
qualit
greater
extent
josamycin
ishimatsu
et
al
henc
macrolid
mani
properti
could
mitig
neutrophil
infl
ammat
central
airway
damag
might
also
improv
aspect
airfl
ow
obstruct
macrolid
also
exert
divers
action
suppress
microbi
virul
factor
shryock
et
al
pecher
wozniak
keyser
although
p
aeruginosa
possess
high
innat
resist
vitro
mic
tabl
antiinfl
ammatori
bacteri
virul
effect
macrolid
antibiot
role
macrolid
therapi
chronic
obstruct
pulmonari
diseas
macrolid
accumul
within
microb
time
suppress
elabor
elastas
lecithinas
pyocyanin
macrolid
also
alter
structur
lp
outer
membran
protein
net
effect
decreas
microbi
adhes
host
cell
hibit
algin
product
macrolid
destroy
pseudomon
biofi
lm
facilit
kill
antibiot
final
subinhibitori
concentr
macrolid
imped
microbi
motil
p
mirabili
p
aeruginosa
inhibit
fl
agellin
synthesi
importantli
activ
also
common
macrolid
seen
use
rokitamycin
ring
macrolid
potent
bactericid
ac
tiviti
suscept
organ
furthermor
differ
among
individu
agent
report
azithromycin
exhibit
greatest
effect
quorum
sens
molinari
et
al
given
immunomodulatori
properti
uniqu
effect
bacteri
pathogen
macrolid
antimicrobi
agent
potenti
serv
uniqu
role
manag
chronic
infl
ammatori
lung
disord
includ
copd
macrolid
increasingli
use
immunomodulatori
properti
wide
rang
chronic
disord
discuss
detail
result
chronic
inflammatori
pulmonari
disord
highlight
goal
present
rational
potenti
use
copd
diffus
panbronchiol
dpb
chronic
infl
ammatori
disord
respiratori
bronchiol
adjac
centrilobular
region
seen
mainli
exclus
japan
present
chronic
cough
exert
dyspnea
reticulonodular
infi
ltrate
chest
radiographi
koyama
gedd
chronic
sinus
almost
alway
note
fact
geograph
locat
diseas
found
presenc
airfl
ow
obstruct
chronic
sinus
nonsmok
immedi
rais
suspicion
dpb
appear
high
resolut
comput
tomographi
chest
characterist
akira
et
al
nishimura
et
al
earli
diseas
cours
h
infl
uenza
pneumonia
cultur
respiratori
secret
mani
case
p
aeruginosa
note
advanc
stage
kadota
et
al
hiratsuka
et
al
percentag
neutrophil
appear
higher
dpb
patient
p
aeruginosa
infect
unexpectedli
neutrophil
chemotact
activ
markedli
increas
dpb
patient
compar
normal
healthi
volunt
kadota
et
al
oda
et
al
similarli
dpb
patient
high
concentr
bal
fl
uid
sakito
et
al
particularli
infect
p
aeruginosa
importantli
histolog
pattern
dpb
includ
bronchiolar
wall
thicken
infi
ltration
lymphocyt
plasma
cell
histiocyt
homma
et
al
investig
group
note
dpb
patient
higher
number
lymphocyt
reduc
ratio
compar
patient
idiopath
bronchiectasi
healthi
subject
muka
et
al
note
elev
bal
fl
uid
dpb
patient
plasma
concentr
correl
concentr
bal
fl
uid
hiratsuka
et
al
fi
nding
support
central
role
infl
ammat
pathogenesi
dpb
suggest
pseudomona
involv
least
associ
sever
involv
may
contribut
acceler
deterior
prior
onset
chronic
macrolid
therapi
prognosi
dpb
dismal
year
surviv
approxim
case
without
p
aeruginosa
infect
less
p
aeruginosa
infect
koyama
gedd
kudoh
et
al
kudoh
colleagu
fi
rst
note
erythromycin
therapi
improv
outcom
dpb
kudoh
et
al
kudoh
et
al
subsequ
case
seri
koyama
gedd
random
placebocontrol
trial
confi
rmed
benefi
cial
effect
yamamoto
importantli
favor
effect
independ
presenc
p
aeruginosa
infect
sawaki
et
al
nagai
et
al
presenc
chronic
respiratori
failur
ohno
et
al
addit
erythromycin
benefi
cial
result
confi
rmed
clarithromycin
takeda
et
al
roxithromycin
ashitani
et
al
nakamura
et
al
azithromycin
increas
mechanist
insight
clinic
effect
macrolid
therapi
dpb
becom
avail
improv
symptom
pulmonari
function
arteri
blood
gase
note
regardless
presenc
pseudomona
infect
although
appear
less
mark
improv
pulmonari
function
patient
bacteria
persist
macrolid
therapi
compar
sputum
cultur
becom
neg
fujii
et
al
effect
macrolid
unlik
exclus
refl
ect
antibacteri
effect
clinic
improv
may
seen
despit
lack
chang
bacteri
isol
number
least
treat
patient
kadota
et
al
nakamura
et
al
numer
investig
demonstr
favor
effect
macrolid
therapi
infl
ammatori
process
dpb
unlik
effect
pure
result
antibacteri
activ
macrolid
maxim
serum
sputum
level
erythromycin
document
mic
clinic
identifi
ed
isol
h
infl
uenza
p
aeruginosa
nagai
et
al
support
antiinfl
ammatori
effect
clinic
treatment
macrolid
shown
decreas
neutrophil
ichikawa
et
al
kadota
et
al
oda
et
al
fujii
et
al
nakamura
et
al
hiratsuka
et
al
neutrophil
chemotact
activ
kadota
et
al
oda
et
al
neutrophilderiv
elastolyticlik
activ
ichikawa
et
al
concentr
ltb
nakamura
et
al
latter
shown
independ
abil
erad
organ
sputum
cultur
howev
patient
bacteria
persist
despit
chronic
macrolid
therapi
less
like
experi
improv
bal
fl
uid
neutrophil
percentag
fujii
et
al
addit
macrolid
therapi
decreas
percentag
bal
lymphocyt
bal
concentr
suggest
primari
effect
underli
pathogen
process
hiratsuka
et
al
summari
data
confirm
mark
benefici
effect
seen
macrolid
therapi
dpb
patient
effect
like
refl
ect
antiinfl
ammatori
properti
agent
addit
potenti
antimicrobi
effect
similar
potenti
effect
copd
evid
asthma
number
biolog
featur
distinct
copd
douw
et
al
sutherland
martin
macrolid
antibiot
util
asthma
forti
year
exampl
troleandomycin
tao
extens
studi
steroidspar
agent
asthma
niven
argyro
inconclus
result
evan
et
al
investig
examin
wide
avail
macrolid
agent
wide
report
outcom
modest
improv
bronchial
hyperrespons
miyatak
et
al
shimizu
et
al
kamoi
et
al
amayasu
et
al
kostadima
et
al
clinic
respons
diffi
cult
judg
uncontrol
studi
garey
et
al
sever
control
trial
publish
recent
cochran
systemat
review
richeldi
et
al
gener
studi
document
modest
symptomat
improv
littl
chang
standard
spirometr
indic
shoji
et
al
amayasu
et
al
investig
provid
mechanist
data
regard
effect
macrolid
therapi
patient
asthma
kraft
colleagu
note
improv
fev
patient
evid
polymeras
chain
reaction
pcr
mycoplasma
chlamydia
upper
lower
respiratori
tract
specimen
patient
pcrposit
patient
treat
clarithromycin
experienc
decreas
mrna
bal
fl
uid
mrna
airway
tissu
pcrneg
patient
treat
clarithromycin
exhibit
decreas
mrna
bal
mrna
airway
tissu
signifi
cant
chang
seen
subject
treat
placebo
black
colleagu
conduct
multicent
multin
studi
adult
mild
moder
asthma
serolog
evid
c
pneumonia
infect
random
patient
roxithromycin
mg
bid
placebo
six
week
modest
increas
peak
expir
fl
ow
note
macrolid
treat
patient
six
week
daytim
nighttim
symptom
show
nonsignifi
cant
improv
improv
qualiti
life
score
differ
two
studi
may
refl
ect
dispar
patient
characterist
baselin
differ
macrolid
administ
differ
defi
nition
atyp
infect
point
may
import
interpret
data
copd
patient
chronic
infect
chlamydia
felt
import
blasi
et
al
bronchiectasi
disord
bronchi
bronchiol
manifest
cough
chronic
sputum
product
dyspnea
wheez
barker
cornerston
therapi
includ
earli
identifi
cation
treatment
acut
exacerb
suppress
microbi
load
treatment
underli
condit
promot
bronchial
hygien
control
bronchial
hemorrhag
surgic
resect
extrem
damagedfoc
diseas
reduct
excess
pulmonari
infl
ammat
barker
like
bronchiectasi
involv
viciou
cycl
infect
subsequ
infl
ammat
mediat
releas
investig
confi
rmed
intens
cellular
infi
ltrate
mononuclear
cell
lymphocyt
macrophag
promin
neutrophilia
increas
express
gaga
et
al
increas
express
potent
chemoattract
ltb
also
report
angril
et
al
richmaneisenstat
et
al
tsang
et
al
addit
patient
colon
potenti
pathogen
organ
experi
greater
infl
ammatori
respons
includ
higher
bal
neutrophil
count
higher
bal
concentr
elastas
myeloperoxidas
angril
et
al
bronchiectasi
patient
p
aeruginosa
sputum
sever
impair
pulmonari
function
greater
sputum
volum
ho
et
al
patient
also
appear
exhibit
highest
concentr
ltb
tsang
et
al
evid
bronchiectasi
character
augment
airway
infl
ammat
appear
relat
bacteri
colon
organ
load
differ
bacteri
speci
small
number
studi
examin
effect
chronic
macrolid
therapi
bronchiectasi
unrel
cystic
fibrosi
week
roxithromycin
mgkg
bid
children
bronchiectasi
increas
airway
hyperreact
experienc
littl
chang
fev
experienc
improv
sputum
purul
airway
respons
koh
et
al
placebocontrol
trial
tsang
colleagu
administ
erythromycin
mg
bid
eight
week
patient
bronchiectasi
tsang
et
al
p
aeruginosa
identifi
ed
baselin
ten
patient
h
infl
uenza
eleventh
patient
treat
macrolid
experienc
improv
spirometri
sputum
volum
parallel
improv
sputum
pathogen
sputum
leukocyt
level
ltb
tsang
et
al
tagaya
colleagu
note
improv
sputum
product
patient
bronchiectasi
n
chronic
bronchiti
n
treat
clarithromycin
mgday
compar
patient
treat
amoxicillin
cefaclor
davi
wilson
examin
thrice
weekli
initi
load
azithromycin
therapi
patient
bronchiectasi
greater
four
exacerb
previou
month
persist
symptom
modest
improv
note
pulmonari
function
although
symptom
score
acut
exacerb
decreas
fi
nding
independ
p
aeruginosa
colon
small
crossov
studi
cymbala
colleagu
note
decreas
acut
exacerb
rate
mean
sputum
volum
chang
pulmonari
function
twice
weekli
azithromycin
therapi
six
month
data
particularli
german
given
frequent
develop
bronchiectasi
follow
aecopd
robust
bodi
literatur
emerg
demonstr
macrolid
antibiot
benefi
cial
treatment
cystic
fi
brosi
cf
lung
diseas
equi
et
al
wolter
et
al
saiman
et
al
southern
et
al
numer
studi
strengthen
conclus
excess
infl
ammat
cf
airway
khan
colleagu
note
higher
infl
ammatori
cell
mediat
infant
cf
even
evid
bacteri
infect
identifi
ed
augment
infl
ammatori
respons
may
intrins
cf
airway
epitheli
cell
dimango
colleagu
note
respons
pseudomona
epitheli
cell
mutat
cystic
fi
brosi
gene
cftr
elabor
higher
level
infl
ammatori
mediat
cell
normal
cftr
infl
ammatori
pulmonari
disord
high
preval
chronic
airway
infect
occur
cf
p
aeruginosa
appear
preval
organ
patient
infect
year
age
trulock
et
al
infect
major
consequ
surviv
cf
patient
harbor
pseudomona
aeruginosa
shorter
cf
patient
uninfect
pseudomona
seri
studi
confi
rmed
benefi
macrolid
therapi
cf
jaff
colleagu
perform
openlabel
studi
daili
azithromycin
children
cf
uk
note
modest
improv
spirometri
azithromycin
therapi
first
wellconstruct
clinic
trial
azithromycin
cf
report
wolter
colleagu
sixti
cf
patient
mean
age
year
randomli
assign
doubleblind
fashion
mg
azithromycin
daili
placebo
month
modest
improv
favor
macrolid
note
spirometri
requir
intraven
antibiot
treatment
acut
exacerb
qualiti
life
equi
colleagu
perform
random
doubleblind
placebocontrol
crossov
studi
cf
patient
age
rang
year
patient
receiv
daili
azithromycin
adjust
bodi
weight
placebo
month
washout
period
patient
cross
altern
therapi
month
modest
improv
fev
note
favor
azithromycin
howev
differ
fvc
fef
pulmonari
exacerb
rate
antibiot
use
chang
exercis
toler
qualiti
wellb
bacteri
cultur
densiti
sputum
level
neutrophil
elastas
largest
trial
macrolid
therapi
cf
complet
saiman
colleagu
perform
multicent
random
doubleblind
placebocontrol
studi
patient
year
age
chronic
infect
p
aeruginosa
percent
predict
fev
patient
treat
weightadjust
azithromycin
dosag
week
treatment
percent
predict
fev
improv
azithromycin
group
wherea
declin
placebo
group
p
furthermor
azithromycintr
patient
less
like
experi
exacerb
treat
placebo
hr
ci
p
subsequ
posthoc
analys
confi
rmed
improv
secondari
endpoint
independ
chang
fev
saiman
et
al
mechan
favor
macrolid
effect
remain
controversi
like
multifactori
martinez
simon
grow
evid
macrolid
may
benefi
cial
directli
alter
p
aeruginosa
biolog
jaff
bush
nguyen
et
al
wagner
et
al
suggest
mechan
includ
microbicid
effect
p
aeruginosa
stationari
oppos
exponenti
growth
phase
reduct
elabor
virul
factor
alter
biofi
lm
format
decreas
bacteri
adher
epitheli
cell
inhibit
bacteri
motil
provid
synergist
effect
antibiot
martinez
simon
like
benefi
cial
antiinfl
ammatori
effect
also
play
role
tabl
jaff
bush
nguyen
et
al
martinez
simon
taken
togeth
avail
data
confi
rm
macrolid
result
clinic
improv
patient
sever
chronic
infl
ammatori
lung
diseas
associ
frequent
bacteri
colon
chronic
infect
data
provid
rational
expans
studi
macrolid
therapi
common
infl
ammatori
airway
disord
includ
copd
given
import
infl
ammat
bacteri
infect
pathogenesi
copd
exacerb
evid
macrolid
may
offer
uniqu
advantag
diseasemodifi
agent
effect
could
multifactori
figur
possibl
support
three
older
publish
studi
first
random
trial
contrast
moxifl
oxacin
clarithromycin
acut
exacerb
confi
rmed
clinic
respons
clarithromycin
patient
despit
achiev
bacteriolog
erad
wilson
et
al
immunomodulatori
effect
macrolid
suggest
explain
discrep
fi
ndrole
macrolid
therapi
chronic
obstruct
pulmonari
diseas
ing
wilson
second
suzuki
colleagu
report
result
openlabel
prospect
random
trial
erythromycin
therapi
mgday
versu
ribofl
avin
mgday
twelv
month
copd
patient
fev
liter
cours
therapi
risk
frequenc
experienc
common
cold
use
predefi
ned
standard
defi
nition
subsequ
acut
exacerb
prospect
evalu
tabl
enumer
signifi
cant
benefi
ts
note
macrolid
therapi
although
result
intrigu
unblind
data
collect
limit
strength
conclus
studi
third
gomez
colleagu
identifi
ed
patient
long
histori
chronic
bronchiti
year
frequenc
fi
episod
per
year
least
two
respiratori
hospit
previou
year
patient
treat
azithromycin
mg
daili
three
day
everi
day
septemb
may
compar
similar
retrospect
group
untreat
copd
patient
although
baselin
differ
treat
patient
control
patient
cours
followup
macrolid
treat
patient
experienc
fewer
exacerb
hospit
per
year
tabl
unexpectedli
exacerb
azithromycin
treat
group
experienc
infect
pneumonia
n
p
aeruginosa
n
k
pneumonia
n
interestingli
within
fi
rst
day
prophylact
treatment
exacerb
caus
pneumonia
isol
diminish
suscept
macrolid
penicillin
control
group
predomin
isol
exacerb
includ
h
infl
uenza
n
pneumonia
n
two
exhibit
diminish
sensit
azithromycin
studi
although
use
suboptim
uncontrol
design
suggest
benefi
cial
respons
seen
chronic
macrolid
prophylaxi
highrisk
copd
patient
mechan
improv
address
could
relat
antibacteri
activ
particularli
regard
h
infl
uenza
recent
two
group
report
small
control
studi
basyigit
colleagu
random
stabl
male
copd
patient
mean
age
yr
fev
predict
clarithromycin
mg
bid
placebo
two
week
addit
standard
bronchodil
therapi
although
baselin
differ
note
treatment
group
clarithromycintr
patient
experienc
signifi
cantli
improv
sputum
infl
ammatori
marker
figur
wherea
physiolog
studi
chang
result
serum
infl
ammatori
marker
qualit
similar
two
group
second
control
studi
patient
moder
sever
copd
mean
age
yr
fev
pred
random
three
month
clarithromycin
mg
sustain
releas
prepar
daili
placebo
contrast
previou
studi
patient
take
inhal
corticosteroid
clarithromycin
associ
signifi
cant
improv
st
georg
respiratori
questionnair
sgrq
symptom
score
unit
physic
function
score
unit
differ
overal
sgrq
score
shuttl
walk
distanc
spirometri
crp
level
rel
short
time
followup
fi
total
aecopd
clarithromycin
placebo
group
differ
seen
quantit
sputum
cultur
obtain
stabl
state
figur
contrast
previou
studi
sputum
ltb
level
differ
clarithromycin
versu
placebo
treatment
although
modest
macrolideassoci
improv
sputum
neutrophil
differenti
neutrophil
chemotaxi
investig
propos
mechanist
rational
improv
chronic
macrolid
therapi
copd
patient
tagaya
colleagu
suggest
chronic
bronchiti
bronchiectasi
patient
treat
clarithromycin
mg
qd
seven
day
experienc
greater
decreas
sputum
volum
patient
treat
parnham
colleagu
treat
copd
patient
mean
fev
liter
azithromycin
mg
daili
three
day
eight
placebo
azithromycin
result
earli
transient
increas
overal
nitrit
plu
nitrat
concentr
later
day
decreas
total
role
macrolid
therapi
chronic
obstruct
pulmonari
diseas
blood
leukocyt
count
serum
crp
oxid
burst
isol
blood
granulocyt
differ
note
sputum
infl
ammatori
marker
azithromycintr
placebotr
patient
potenti
risk
chronic
macrolid
therapi
patient
popul
macrolid
use
may
associ
increas
risk
subsequ
infect
macrolid
nonsuscept
bacteria
particularli
pneumonia
klugman
lonk
vanderkooi
et
al
increas
macrolidenonsuscept
pneumonia
report
chronic
erythromycin
aberg
et
al
kasahara
et
al
clarithromycin
kasahara
et
al
azithromycin
therapi
gomez
et
al
aberg
et
al
similarli
agent
may
associ
gastrointestin
intoler
saiman
et
al
basyigit
et
al
cymbala
et
al
cardiac
toxic
iannini
milberg
et
al
ototox
haydon
et
al
swanson
et
al
wallac
et
al
frequenc
sever
toxic
vari
agent
dose
durat
therapi
potenti
complic
high
preval
medic
comorbitidi
copd
patient
highlight
potenti
risk
chronic
empir
macrolid
therapi
patient
popul
macrolid
antibiot
assum
import
role
manag
aecopd
broadspectrum
coverag
excel
safeti
profi
le
increasingli
data
becom
avail
macrolid
benefi
cial
effect
independ
antibacteri
activ
potent
antiinfl
ammatori
effect
may
particularli
import
chronic
infl
ammatori
airway
disord
latter
action
may
greatest
benefi
select
patient
copd
disord
character
augment
pulmonari
infl
ammat
baselin
frequent
bacteri
colonizationinfect
recurr
exacerb
diseas
increas
lung
infl
ammat
role
chronic
macrolid
therapi
patient
requir
addit
studi
better
defi
ne
seri
concern
includ
treatmenteffect
chronic
macrolid
therapi
copd
patient
treat
maxim
convent
therapi
macrolid
attenu
baselin
infl
ammat
prevent
attenu
aecopd
episod
therapeut
effect
refl
ect
antimicrobi
activ
immunomodulatori
effect
therapeut
effect
vari
host
factor
includ
diseas
sever
presenc
bronchiectasi
presenc
baselin
colon
typic
includ
p
aeruginosa
atyp
pathogen
includ
c
pneumonia
presenc
comorbid
toxic
chronic
therapi
copd
patient
riskbenefi
macrolid
therapi
copd
patient
resolut
vital
question
requir
addit
welldesign
placebocontrol
trial
knowledg
three
larg
studi
current
ongo
yield
answer
vital
question
widespread
use
macrolid
prophylaxi
recommend
copd
patient
